NCT04405076View on ClinicalTrials.gov

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

PHASE2CompletedINTERVENTIONAL

Enrollment

660

Participants

Timeline

Start Date

May 29, 2020

Primary Completion Date

October 28, 2021

Study Completion Date

October 28, 2021

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL

Biological: mRNA-1273

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

BIOLOGICAL

mRNA-1273.351

Sterile liquid for injection

Trial Locations (8)

28403

Trial Management Associates, Wilmington

31406

Meridian Clinical Research, Savannah

57049

Meridian Clinical Research, Dakota Dunes

64114

Alliance for Multispecialty Research, Kansas City

67114

Alliance for Multispecialty Research, Newton

68701

Meridian Clinical Research, Norfolk

76904

Benchmark Research, San Angelo

78705

Benchmark Research, Austin

All Listed Sponsors

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

ModernaTX, Inc.

INDUSTRY

NCT04405076 - Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | Biotech Hunter | Biotech Hunter